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ABSTRACT
The incidence of invasive fungal infections (IFIs) has been following an upward trend over time, due to a
continuous increase in the number of patients at risk, while the prognosis remains poor. In the last
10 years, the lipidic formulations of amphotericin B, voriconazole and a new family of antifungal drugs,
the echinocandins, have been added to the traditional antifungal agents, for decades limited to just a few
drugs such as amphotericin B deoxycholate, ﬂucytosine and, later, ﬂuconazole and itraconazole. These
additions have improved both the results and the understanding of antifungal therapy, while at the
same time making it more complex, with new questions arising that remain to be answered. This article
reviews the mechanisms of action, spectrum of activity, pharmacology, administration, adverse effects
and indications of each of the antifungal agents currently commercialised for the treatment of IFI.
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voriconazole
Clin Microbiol Infect 2006; 12 (suppl 7): 53–64
CLASSIFICATION
Nine systemic antifungal drugs belonging to four
families have been approved for the treatment of
invasive fungal infections (IFIs). Table 1 shows
the classiﬁcation of these systemic antifungal
agents and their mechanisms of action.
AMPHOTERICIN B DEOXYCHOLATE
Amphotericin B deoxycholate is a natural poly-
enic antibiotic obtained from Streptomyces nodosus.
It is usually combined with a deoxycholate
suspension in order to achieve the solubility
needed for its parenteral administration. It binds
ergosterol, which is the main component in the
fungal cell membrane, and increases fungal per-
meability, thus causing cell death. Amphotericin
B deoxycholate also acts by means of oxidative
mechanisms damaging the cell membrane.
Since the standardised and reliable determin-
ation of amphotericin B activity in the different
species of pathogenic fungi is not yet deﬁnitive,
the results of the available susceptibility studies
should be evaluated cautiously. The amphotericin
B deoxycholate spectrum of action includes the
majority of fungi that are pathogenic for humans:
Aspergillus spp., Candida spp., Cryptococcus neofor-
mans, Blastomyces dermatitidis, Coccidioides immitis,
Paracoccidioides brasilensis, Histoplasma capsulatum
and Penicillium marneffei. It is also active against
the mucormycosis, hyalohyphomycosis and pha-
eohyphomycosis agents. Resistance to amphoter-
icin B deoxycholate is infrequent and limited to
some isolates of Candida lusitaniae, Candida glab-
rata, Candida guilliermondii, Aspergillus terreus,
Scedosporium apiospermun, Scedosporium proliﬁcans,
Fusarium spp. and Trichosporon spp. [1,2]. The
mechanism by which Candida lusitaniae develops
resistance to amphotericin B deoxycholate is a
decrease in the synthesis of ergosterol in its
membrane [3]. This mechanism of resistance
could explain why the susceptibility of Candida
albicans to amphotericin B deoxycholate decreases
after the strain has been exposed to ﬂuconazole
[4]. The spectrum of activity of amphotericin B is
the same for the different formulations.
Amphotericin B deoxycholate is fungicidal, has
a concentration-dependent activity and shows a
prolonged post-antibiotic effect (PAE) according
to some experimental studies [5]. Its pharmacoki-
netic proﬁle is complex and has not been sufﬁ-
ciently studied. It binds to plasma proteins 95% of
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the time and involves the liver, spleen, bone
marrow, kidneys and lungs. In spite of the fact
that amphotericin B deoxycholate barely crosses
the meningeal membrane when this is inﬂamed, it
is active in cryptococcal meningitis. Plasma clear-
ance is slow, although slightly faster in children,
and its terminal half-life is 5 days. Most of the
drug is degraded in tissue, with only a small
percentage being eliminated in urine or bile. Dose
adjustment is not required in cases of hepatic or
renal impairment or in haemodialysis. Ampho-
tericin B deoxycholate is the only systemic anti-
fungal agent that is not contraindicated during
pregnancy [1]. The most frequent adverse effects
of amphotericin B are those related to infusion
and nephrotoxicity. Half of the patients receiving
amphotericin B deoxycholate suffer adverse ef-
fects related to infusion, e.g., fever, chills, shiver-
ing, myalgia and ⁄ or nausea. These effects mainly
occur with the ﬁrst dose administered; however,
with subsequent doses, with pre-medication
(hydrocortisone 0.5 mg ⁄ kg or acetaminophen
10 mg ⁄ kg) and with a reduction in the infusion
rate, their intensity progressively decreases and
they ﬁnally disappear. Nephrotoxicity, deﬁned as
a two-fold increase in the baseline levels of
creatinine, occurs in 30% of patients treated with
amphotericin B deoxycholate [6]. It induces vaso-
constriction in the renal afferent arteriole and an
imbalance in tubular permeability, thereby caus-
ing a reduction in the glomerular ﬁltration rate,
tubular acidosis and loss of potassium and mag-
nesium. Nephrotoxicity usually stabilises during
the course of the treatment and is reversed when
the treatment is ﬁnished. The risk of nephrotox-
icity increases with the total accumulated dose of
amphotericin B deoxycholate, male sex, previous
renal impairment and high co-morbidity. Patients
developing renal failure during treatment with
amphotericin B deoxycholate show higher mor-
tality rates [6]. The administration of physiologi-
cal saline solution reduces the risk of
nephrotoxicity associated with amphotericin B
deoxycholate [7].
It has recently been demonstrated that adminis-
tration of amphotericin B deoxycholate by slow,
continuous intravenous infusion (over 24 h or at a
rate of infusion <0.08 mg ⁄ kg ⁄h) is associated with
a lower incidence of adverse effects related to
nephrotoxicity and infusion when compared with
the usual administration over 4 h [8]. This beneﬁ-
cial effect has also been demonstrated in patients
who have received allogeneic haemopoietic stem-
cell transplants (HSCTs) and in those receiving
simultaneous treatment with other nephrotoxic
drugs [9]. The administration of amphotericin B
deoxycholate as a continuous infusion allows
amphotericin B doses of up to 2 mg ⁄kg ⁄day, with
no additional toxicity [10]. The efﬁcacy of ampho-
tericin B deoxycholate administered by continuous
infusion is, however, still under discussion, since,
according to experimental data, its antifungal
activity is concentration-dependent. However,
according to both of these studies, amphotericin B
deoxycholate administered by continuous infusion
reduces overallmortality as comparedwith admin-
istration at the standard rate [8,9].
The main interactive effect of amphotericin B
deoxycholate is an increase in the plasma levels of
those drugs that undergo renal elimination, since
it reduces glomerular ﬁltration. Co-administra-
tion of neutrophils and amphotericin B deoxych-
olate is associated with severe acute pulmonary
damage [1].
Amphotericin B deoxycholate remains the
antifungal agent of choice against many IFIs,
Table 1. Classiﬁcation of the systemic antifungal agents available and their mechanisms of action
Families Compounds Mechanisms of action
Polyene antibiotics Amphotericin B deoxycholate Binds to ergosterol + oxidative
damage to fungal cells
Lipid formulations of amphotericin B:
Amphotericin B lipid complex
Amphotericin B colloidal dispersion
Liposomal amphotericin B
Pyrimidines Flucytosine Inhibition of DNA synthesis
Azoles Fluconazole Inhibition of ergosterol synthesis
Itraconazole
Voriconazole
Echinocandins Caspofungin Inhibition of glucan synthesis
54 Clinical Microbiology and Infection, Volume 12 Supplement 7, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (suppl 7), 53–64
including invasive candidiasis, cryptococcosis,
mucormycosis, histoplasmosis, blastomycosis,
coccidioidomycosis, penicillosis, sporotricho-
sis and phaeohyphomycosis. The amphotericin B
deoxycholate dosage depends on the type of
infection, the species and the host factors. The
dose recommended for invasive candidiasis is:
0.6 mg ⁄kg ⁄day for infections caused by Candida
albicans in non-neutropenic patients; 0.7–
1 mg ⁄kg ⁄day for patients with neutropenia; and
1 mg ⁄kg ⁄day for infections caused by Candida
glabrata and Candida krusei [11]. In the case of
mucormycosis, the recommended dose is 1–
1.5 mg ⁄kg ⁄day [1].
It has traditionally been recommended to start
amphotericin B deoxycholate administration after
a previous test dose of 1 mg, increasing the doses
thereafter. This empirical recommendation delays
the administration of the full dose of the drug,
which is vital in these severe cases of IFI, and thus
does not seem to be justiﬁed nowadays. In
addition, initial administration of amphotericin
B deoxycholate at a high dose (1 mg ⁄ kg ⁄day by
continuous infusion) without a previous test dose
has been proved to be safe in a clinical study [10].
Amphotericin B deoxycholate is diluted in
500 mL of 5% dextrose through an independent
central venous catheter, and is administered with
1000 mL of saline solution, and when possible, by
24-h continuous infusion. Treatment with amph-
otericin B deoxycholate requires monitoring of
creatinine, sodium, potassium, bicarbonate and
magnesium levels [8–10].
AMPHOTERICIN B LIPID
FORMULATIONS
Three lipid formulations of amphotericin B deo-
xycholate are currently available: amphotericin B
lipid complex, amphotericin B colloidal dispersion
and liposomal amphotericin B. In comparison
with amphotericin B deoxycholate, these com-
pounds reach higher concentrations in the liver
and spleen, and lower concentrations in the
kidneys. Lipid formulations have the same
mechanism of action and the same spectrum of
activity as amphotericin B deoxycholate [12].
Lipid amphotericin B formulations, especially
liposomal amphotericin B, are less nephrotoxic
than amphotericin B deoxycholate [13–15].
Table 2 shows the renal toxicity associated with
the different amphotericin B formulations. Infu-
sion-related adverse effects are frequent with
lipid amphotericins [13], amphotericin B colloidal
dispersion being responsible even more fre-
quently than amphotericin B deoxycholate, fol-
lowed by amphotericin lipid complex and
liposomal amphotericin B [16,17]. Cases of severe
pulmonary reactions have been described during
the administration of amphotericin B lipid com-
plex, some of them leading to death [18]. With the
ﬁrst dose of liposomal amphotericin B, an acute
reaction affects up to 35% of patients, with three
possible presentations: (i) chest pain, dyspnoea
and hypoxia; (ii) severe abdominal, ﬂank or leg
pain; or (iii) ﬂushing and urticaria. These symp-
toms, which may be severe, are reversed with the
suspension of the infusion and administration of
diphenhydramine, and do not necessarily appear
again with subsequent doses of liposomal amph-
otericin B [19].
Randomised studies comparing the efﬁcacy of
amphotericin B deoxycholate with that of the
lipid formulations of amphotericin B are scarce.
According to these few studies, amphotericin B
colloidal dispersion is as efﬁcacious as amphoter-
icin B deoxycholate in the treatment of invasive
aspergillosis [17] as well as in the empirical
treatment of persistent neutropenic febrile
patients [13]. This traditional indication for
Table 2. Nephrotoxicity of the dif-
ferent lipid formulations of ampho-
tericin in clinical trials
Nephrotoxicitya (%) Reference
Amphotericin B deoxycholate infused
over 24 h vs. 4 h
15 vs. 28 [8]
Amphotericin B colloidal dispersion
vs. amphotericin B deoxycholate
20 vs. 52 [13]
Liposomal amphotericin B
vs. amphotericin B deoxycholate
19 vs. 34 [15]
Liposomal amphotericin B
vs. amphotericin B lipid complex
14 vs. 42 [17]
aDeﬁned as two times baseline creatinine level during treatment.
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antifungal therapy has recently been questioned,
since empirical treatment seems to be neither
more effective than placebo nor an improvement
upon the results obtained with directed antifun-
gal treatment [20].
Liposomal amphotericin B is more effective
than amphotericin B deoxycholate in the treat-
ment of severe histoplasmosis in AIDS patients
[21], and is similarly effective in the empirical
treatment of neutropenic patients with persistent
fever [15]. Lipid formulations are considerably
more expensive than conventional amphotericin B
[12].
Lipid amphotericin B formulations are indicat-
ed for the treatment of those IFIs in which
amphotericin B deoxycholate has failed or has
caused adverse effects. In addition, liposomal
amphotericin B has been approved for the treat-
ment of neutropenic patients with persistent fever
at a dose of 3 mg ⁄ kg ⁄day [15]. Lipid formulations
of amphotericin B require higher doses to achieve
an efﬁcacy equal to that of amphotericin B
deoxycholate. In general, 5 mg ⁄ kg ⁄day of lipid
formulations is equivalent to 1 mg ⁄ kg ⁄day of
conventional amphotericin B. The recommended
dose of liposomal amphotericin B in both adult
and paediatric patients is 3–5 mg ⁄ kg ⁄day,
depending on the severity and cause of the
infection. Liposomal amphotericin B is adminis-
tered intravenously by continuous infusion for
30–60 min, diluted in 5% glucose solution, at a
concentration of 0.20–2 mg ⁄mL. Amphotericin B
lipid complex is administered at a dose of
5 mg ⁄ kg ⁄day by intravenous infusion, diluted in
5% glucose solution, at an infusion rate of
2.5 mg ⁄ kg ⁄h. The manufacturer of this product
recommends an initial test dose of 1 mg. The
recommended dose of amphotericin B colloidal
dispersion is 3–4 mg ⁄kg ⁄day [12].
FLUCYTOSINE
Flucytosine is a ﬂuorinated cytosine analogue that
acts by inhibiting DNA synthesis in the fungus.
Its spectrum of activity is limited to Candida spp.
and Cryptococcus neoformans. When combined
with amphotericin B deoxycholate, it shows a
synergistic or additive effect against both species.
Primary resistance to ﬂucytosine is rare, except
for Candida krusei. Secondary resistance rapidly
develops when ﬂucytosine is used in monothera-
py [1].
Flucytosine is considered to be an antifungal
agent with a time-dependent activity and a short
PAE [5]. Oral absorption of ﬂucytosine is rapid
and complete. It barely binds plasma proteins,
and has good tissue penetration; its levels in
cerebrospinal ﬂuid (CSF) reach nearly 75% of
those in plasma. Flucytosine’s half-life is 4 h. It is
eliminated in urine without previous metabolic
change; dose adjustment is therefore needed in
cases of renal impairment. Bone marrow suppres-
sion, nausea and vomiting and, especially, skin
rash are the main adverse effects [1]. Cytosine
arabinoside inhibits ﬂucytosine, so their com-
bined administration is contraindicated. Flucyto-
sine is contraindicated during pregnancy. The
main indication for ﬂucytosine is the treatment of
cryptococcal meningitis, in combination with
amphotericin B deoxycholate. This combination
is the treatment of choice because, when com-
pared with amphotericin B deoxycholate in
monotherapy, it takes much less time to achieve
CSF sterilisation [22,23]. The recommended dose
of ﬂucytosine is 25–37 mg ⁄ kg ⁄ 6 h administered
orally. In cases of renal impairment, monitoring of
ﬂucytosine plasma levels is recommended, in
order to maintain optimum levels (between 30
and 80 mg ⁄L) [11]. When creatinine clearance is
26–50 mL ⁄min, the total dose must be reduced to
75 mg ⁄ kg ⁄day, and when creatinine clearance is
13–25 mL ⁄min, to 37 mg ⁄ kg ⁄day. In cases of
endocarditis and meningitis caused by Candida
spp., it is recommended to combine ﬂucytosine
with amphotericin B deoxycholate [1,11]. Flucyt-
osine, when combined with ﬂuconazole, is an
alternative treatment for cryptococcal meningitis
[23]. Flucytosine is available as 250-mg and 500-
mg capsules, and as a solution, 2.5 g in 250 mL,
for intravenous administration.
AZOLES
Azoles constitute a family of systemic antifungal
agents that are classiﬁed according to the number
of nitrogen atoms in their ring structure, either as
imidazoles (miconazole and ketoconazole), with
two nitrogen molecules, or as triazoles (itracon-
azole, ﬂuconazole and voriconazole), with three
molecules. Imidazoles have been displaced by
triazoles in the treatment of IFI [1].
Azoles inhibit lanosterol-14a-demethylase, thus
interrupting the conversion of lanosterol to ergos-
terol. Depletion of ergosterol, a major component
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of the fungal cell membrane, alters its permeab-
ility and causes either death of the fungus or
inhibition of growth [2].
The spectrum of activity of ﬂuconazole
includes Candida spp. (except for Candida krusei),
Cryptococcus neoformans, Trichosporon spp., H. cap-
sulatum, Coccidioides immitis, B. dermatitidis, Para-
coccidioides brasilensis and Sporothrix schenckii.
Itraconazole is also active against Aspergillus
spp., and voriconazole extends its activity, in a
variable fashion, to Fusarium spp. and Scedospori-
um apiospermum. Azoles are not active against
zygomycetes and Scedosporium proliﬁcans.
Primary resistance to azoles is well-known,
Candida krusei and ﬂuconazole being the best
example of this [2]. Secondary resistance during
treatment is well-documented in Candida strains
causing stomatitis and oesophagitis in AIDS
patients and in HSCT patients [24,25]. Cross-
resistance with other azoles is not universal, but
in general those strains resistant to ﬂuconazole
have higher MICs of other azoles as well.
Increased use of azoles, especially ﬂuconazole, is
associated with an increase in less susceptible
Candida species, such as Candida glabrata and
Candida krusei. Similarly, the occurrence of infec-
tions caused by zygomycetes has been related to
the introduction of voriconazole for treatment and
prophylaxis in HSCT recipients [26,27].
Standardisation of azole susceptibility testing
has allowed, for the ﬁrst time in the context of
antifungal treatment, the establishment of clinic-
ally useful cut-off points, as suggested by recent
data in patients with candidaemia in whom a
close correlation among dosage, the MIC of
ﬂuconazole and response to therapy has been
demonstrated [28].
Triazoles are fungistatic agents that are active
against Candida spp., their activity being time-
dependent and showing a prolonged PAE [5].
These drugs require initial loading doses in order
to rapidly reach a steady state. Triazoles inhibit
the cytochrome P450 enzyme system, thus caus-
ing numerous pharmacological interactions of
variable intensity, depending on the compound
used (Table 3). Triazoles are contraindicated
during pregnancy, and their use is not recom-
mended during breast-feeding. Unlike other
antifungal agents, triazoles are available for both
oral and intravenous administration, and are
therefore the drugs of choice in the sequential
treatment of IFI.
Fluconazole
Fluconazole exhibits excellent oral absorption
(90%), inﬂuenced by neither oral intake nor
gastric pH. Protein binding is very minimal,
unlike with other triazoles. In CSF, ﬂuconazole
levels reach nearly 70% of those in plasma. It is
mainly eliminated without metabolic change
through glomerular ﬁltration, and thus reaches
high renal levels. It requires a 50% reduction in
dose whenever creatinine clearance is below
50 mL ⁄min, and a 25% reduction if creatinine
clearance is c. 20 mL ⁄min. In haemodialysis
patients, an entire dose of ﬂuconazole must be
administered after each haemodialysis session
[29]. Its half-life is 30 h, but in neonates the half-
life is longer, so in the ﬁrst 2 weeks of life the
interval between doses is 72 h, and in the third
and fourth weeks it is 48 h.
Fluconazole is the safest and best tolerated
triazole. Its administration is interrupted by
adverse events in only 1.5% of patients. Nausea,
vomiting, skin rash and transient increases in the
plasma levels of transaminases are the most
common adverse effects [29].
Fluconazole inhibits cytochrome P450, CYP3A4
and CYP2C9 isoenzymes. The pharmacological
interactions of ﬂuconazole are described in
Table 3. Simultaneous administration of astemiz-
ole, terfenadine and cysapride with ﬂuconazole is
contraindicated [29].
Fluconazole is indicated for front-line treatment
of invasive candidiasis in patients not previously
treated with azoles as well as for the sequential
treatment of both this IFI [11] and cryptococcal
meningitis [22,23]. Fluconazole is the treatment of
choice for meningitis caused by Coccidioides imm-
itis. In primary prophylaxis, ﬂuconazole is effect-
ive in the prevention of invasive candidiasis in
allogeneic HSCT recipients [30], cryptococcosis in
AIDS [31] patients and IFI in infants with birth
weights of less than 1000 g [32]. In secondary
prophylaxis, ﬂuconazole is efﬁcient in the pre-
vention of relapsing cryptococcal meningitis and
coccidiomycosis in HIV-infected patients [31].
Itraconazole
Itraconazole is available as capsules, as oral
solution and, recently, in solution for intravenous
administration. These last two formulations have
cyclodextrin as an excipient, which facilitates
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itraconazole solubility. The oral absorption of
itraconazole capsules is irregular, and increases
with gastric pH, food and cola drinks. The oral
solution is better absorbed than are capsules;
absorption increases with fasting and does not
change with gastric pH variations. Itraconazole
circulates strongly bound to plasma proteins and
barely penetrates the CSF. It is metabolised in the
liver and eliminated in bile and urine. Cyclodex-
trin is eliminated without metabolic change
through glomerular ﬁltration. In patients with
hepatic dysfunction, a reduction in the dose of
itraconazole is required. In patients with creati-
nine clearance below 30 mL ⁄min, both oral and
intravenous solutions of itraconazole are contra-
indicated [33]. Cyclodextrin, the excipient used
for itraconazole and voriconazole formulations,
produces pancreas adenocarcinoma in rats. The
clinical relevance of this carcinogenic effect is
unknown [34].
Itraconazole’s adverse effects are rare and, in
general, mild. Nausea, vomiting, diarrhoea and
Table 3. Drug interactions with azoles
Drugs Type of interaction Fluconazole Itraconazole Voriconazole
Rifampin
Phenobarbital
Decrease
azole levels
Caution Not recommended
Caution
Contraindicated
Contraindicated
Carbamazepine Caution Contraindicated
Nevirapine Caution Not recommended Caution
Astemizol,
terfenadine,
cisapride,
pimozide,
quinidina
Increase
drug levels
Contraindicated Contraindicated Contraindicated
Disopyramide Caution
Dofetilide,
mizolastide
levomethadyl
Contraindicated
Sirolimus Caution Contraindicated
Cyclosporin Caution Caution Dose should be halved
Tacrolimus Caution Caution Dose should be reduced to a third
Ergot alkaloids Caution Contraindicated
Oral anticoagulants Caution Caution Caution
Sulfonylureas Caution Caution
Simvastatina,
lovastatina,
atorvastatina
Caution Contraindicated Caution
Midazolam oral,
triazolam
Caution Contraindicated Caution
Vinca alkaloids Caution Caution
Trimetrexate,
docetaxel,
busulfan,
cilostazol,
eletriptan
Caution
Halofantrine Caution
Alfentanil Caution Caution
Omeprazole Dose should be halved
Zidovudine Caution
Calcium channel
blockers
Caution
Phenytoin
Rifabutim
Two-way
interactions
Caution
Caution
Caution
Not recommended
Not recommended
Not recommended
Ritonavir Caution Caution Contraindicateda
Efavirenz Caution Contraindicated
Contraindicated: concomitant administration is contraindicated.
Caution: special precautions and monitoring of patient and drug levels are required.
aVoriconazole co-administered with 400 mg twice-daily of ritonavir is contraindicated. There are no data on the interaction
when boosting doses of ritonavir (RTV) (100–400 mg ⁄day) are given with voriconazole.
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asymptomatic transaminase elevations are the
main adverse effects. Intolerance to itraconazole
is more frequently observed with the oral solu-
tion. Isolated cases of severe hepatotoxicity, with
hepatic failure and death, have also been
described. Intravenous itraconazole exhibits a
negative inotropic effect and therefore its use
should be avoided in patients with cardiac dys-
function [34].
Itraconazole interactions are more frequent and
signiﬁcant than those of ﬂuconazole, as shown in
Table 3. Simultaneous administration of itracon-
azole and astemizole, terfenadine, cisapride,
lovastatin, simvastatin, atorvastatin, quinidine,
oral midazolam, rifampin, rifabutin, phenytoin
and ergotamine alkaloids is contraindicated.
Monitoring of itraconazole plasma levels is
recommended when administering capsules or
oral solution, in order to achieve concentrations
above 0.5 mg ⁄L, which seem to provide protec-
tion against IFI. With the oral solution, levels
‡0.5 mg ⁄L are reached in 90% of patients receiv-
ing itraconazole [35]. The efﬁcacy and safety of
itraconazole in children have not been assessed,
so its use is not recommended in this patient
population [34].
Itraconazole, in oral and intravenous solution,
is indicated for the empirical antifungal treatment
of persistent febrile neutropenia, since its efﬁcacy
is similar to that of amphotericin B deoxycholate
and it is better tolerated [36]. Itraconazole is the
treatment of choice in sporotrichosis and endemic
mycoses with no meningeal involvement in im-
munocompetent patients. It has also been ap-
proved as an alternative treatment for invasive
aspergillosis, based on non-comparative open
studies [37,38]. Itraconazole solution, in both oral
and intravenous formulations, is as effective as
ﬂuconazole in the prophylaxis of IFI in haemato-
logical patients with neutropenia and in HSCT
recipients [35,39]. Continuous prophylaxis with
itraconazole reduces the incidence of IFI in chil-
dren with chronic granulomatous disease [40]. In
AIDS patients, itraconazole is recommended for
primary and secondary prophylaxis of histoplas-
mosis, and it is also very effective in the preven-
tion of relapsing infection caused by Penicillium
marneffei [41].
The recommended dose of itraconazole by
injection is 200 mg twice-daily for the ﬁrst four
doses, followed by 200 mg once-daily for up to
14 days. Each intravenous dose should be infused
over 1 h. Afterwards, treatment should be con-
tinued with itraconazole oral solution or capsules
200 mg twice-daily [34].
Voriconazole
Voriconazole is the ﬁrst of a new generation of
triazoles, available in capsules and cyclodextrin
solution for intravenous administration. Its oral
bioavailability is high, being maximum when
administered during fasting (before meals or food
intake). Its half-life is 6–12 h, and 58%of thedrug is
usually bound to plasma proteins. It reaches very
high levels in the CSF. Voriconazole is metabolised
in the liver by the CYP450 enzyme system, espe-
cially the CYP2C19, CYP2C9 and CYP3A4 isoen-
zymes. In patients with moderate renal failure
(creatinine clearance <50 mL ⁄min), intravenous
administration should be avoided. In patients with
Child’s A and B grades of liver dysfunction, the
recommended voriconazole maintenance dose
should be reduced, in light of the low weight
(under 40 kg) of the patients. Treatment with
voriconazole is not recommended in patients with
Child’s C grade of cirrhosis [42]. Voriconazole is
well-tolerated generally, its most common adverse
effects being transient visual alterations, with
blurred vision, colour change, photosensitivity
and ⁄ or photophobia. Other adverse effects include
nausea, headache, skin rash and reversible transa-
minase elevations. Uncommon cases of serious
hepatic reactions, including fulminant hepatic
failure, have also been described [42].
Since voriconazole is metabolised by the
CYP3A4 pathway, it has many and very relevant
drug interactions (Table 3). Some of them are with
astemizole, terfenadine, cisapride, pimozide or
quinidine with voriconazole when simulta-
neously administered, and these are contraindi-
cated due to the risk of prolonged QTc, and the
risk of torsade de pointes increases with such
combinations. It is also contraindicated in combi-
nation with rifampin, phenobarbital and carb-
amazepine, since these drugs lead to a rapid and
profound drop in voriconazole plasma levels; and
it is contraindicated in combination with siroli-
mus, due to the increased levels of this immuno-
suppressant when given simultaneously with
voriconazole, and with ergotaminic alkaloids,
because of the risk of ergotism. It is also recom-
mended to avoid the concomitant use of voricon-
azole with rifabutin and phenytoin [42].
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Voriconazole is the treatment of choice for
invasive aspergillosis. In a randomised open
study, it demonstrated a higher efﬁcacy than
amphotericin B deoxycholate, improving the sur-
vival rate [43]. Voriconazole is effective as salvage
therapy in cases of invasive candidiasis and
cryptococcosis and as front-line treatment for
Fusarium spp. and Scedosporium apiospermum
infections [44]. Voriconazole was not approved
for the empirical management of persistent febrile
neutropenia, since it did not meet the discussed
criteria of equivalence with liposomal amphoter-
icin B [45].
The recommended dose of intravenous voric-
onazole is 6 mg ⁄kg ⁄ 12 h on the ﬁrst day of
treatment, followed by 4 mg ⁄kg ⁄ 12 h thereafter.
In patients weighing <40 kg, these doses must
be reduced to 200 mg ⁄ 12 h and 100 mg ⁄ 12 h,
respectively. Voriconazole is not recommended
for children less than 2 years of age [42].
CASPOFUNGIN
Caspofungin belongs to a new class of antifungal
drugs, the echinocandins, which act by non-
competitively inhibiting the synthesis of 1,3-b-
glucan, an essential component of the cell walls in
many yeasts and moulds, which is not present in
the cell walls of mammals. Caspofungin has
fungicidal activity against all Candida species as
well as potent inhibitory activity in vitro against
Aspergillus spp. It is not active against Cryptococ-
cus neoformans, Trichosporon spp., Scedosporium
proliﬁcans, Rhizopus spp. and Fusarium spp. [46].
Caspofungin activity against Candida spp. is
fungicidal and concentration-dependent, and has
a prolonged PAE [5]. It is available for intraven-
ous use only, and more than 90% of the drug
circulates bound to plasma proteins. In liver,
kidneys, spleen and lungs, it reaches concentra-
tions higher than those in plasma. It is metabo-
lised in the liver, independently of the CYP450
system. A reduction of the caspofungin mainten-
ance dose to 35 mg daily is recommended in cases
of moderate hepatic dysfunction, and interruption
of the drug is recommended in cases of severe
hepatic failure. Caspofungin does not require
dose adjustment for renal failure or in haemodi-
alysis patients. Its prolonged half-life, 9–11 h,
allows administration of a single daily dose [46].
Caspofungin is safe and well-tolerated. Its main
adverse effects are fever, phlebitis, headache and
reversible moderate elevation of transaminases.
Simultaneous administration with efavirenz,
carbamazepine, phenytoin, phenobarbital or dex-
amethasone can reduce caspofungin efﬁcacy;
therefore, increasing the dose to 70 mg daily is
recommended when it is given concomitantly
with any of these drugs. Cyclosporin increases the
caspofungin AUC in 35% of cases and causes a
transient elevation of transaminases, so concom-
itant use of the two drugs should be limited to
those patients in whom the beneﬁts are expected
to outweigh the potential risks [46]. In recent
studies, the simultaneous administration of
caspofungin and cyclosporin was not associated
with an increased risk of relevant hepatic toxicity
[47,48].
Caspofungin is indicated for the treatment of
invasive candidiasis in adult patients, based on
a randomised study in which caspofungin was
demonstrated to be as effective as amphotericin
B deoxycholate, but with less toxicity [49]. It is
indicated for the management of invasive asper-
gillosis in adult patients following clinical fail-
ure or intolerance to amphotericin B
deoxycholate, lipid formulations of amphotericin
B and ⁄ or itraconazole, according to the data
from a non-comparative open study [50]. Final-
ly, caspofungin has been approved for the
empirical treatment of patients with persistent
febrile neutropenia, since it is as effective as,
and better tolerated than, liposomal amphoteri-
cin B [51].
A single 70-mg loading dose should be admin-
istered on day 1, followed by 50 mg daily there-
after. In patients weighing more than 80 kg, after
the initial 70-mg loading dose, 70 mg daily is
recommended. Caspofungin has not been studied
in paediatric patients, so its use in patients under
18 years of age is not recommended [46].
Table 4 shows dosages and methods of admin-
istration for all antifungal agents in the treatment
of adults and special populations.
COMBINATION ANTIFUNGAL
THERAPY
Combination therapy has shown superior results
to monotherapy in several bacterial and viral
infections; it has thus been proposed for the
treatment of IFIs, especially aspergillosis. The
clinical rationale for combination antifungal
therapy is limited to the results of only three
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prospective randomised studies. The ﬁrst study,
carried out in patients with cryptococcal menin-
gitis, demonstrated that the combination of
amphotericin B deoxycholate (0.3 mg ⁄kg ⁄day)
and ﬂucytosine (150 mg ⁄ kg ⁄day) was more
effective than amphotericin B deoxycholate as
monotherapy, with a higher incidence of re-
sponse, fewer relapses and more rapid CSF
sterilisation [52]. The second study, performed in
HIV-infected patients with cryptococcal menin-
gitis, demonstrated that with the combination of
amphotericin B deoxycholate (0.7 mg ⁄kg ⁄day)
and ﬂucytosine (100 mg ⁄ kg ⁄day), it takes less
time to sterilise CSF than with amphotericin B
deoxycholate as monotherapy [22]. Mortality rates
were the same in both groups. The third study
demonstrated that the combination of amphoter-
icin B deoxycholate (0.7 mg ⁄kg ⁄day) with ﬂucon-
azole (800 mg ⁄day) improves the rates of clinical
and microbiological response in non-neutropenic
patients with candidaemia when compared with
ﬂuconazole as monotherapy, although it did not
decrease the rate of mortality [53].
Concerning invasive aspergillosis, no random-
ised prospective studies assessing combination
antifungal therapy are available. In an observa-
tional study performed in patients with invasive
aspergillosis in whom amphotericin B deoxycho-
late had failed, treatment with caspofungin plus
voriconazole reduced mortality when compared
with an historical control group treated with
voriconazole alone [54]. However, reliance upon
these results is limited by several factors inherent
to the study: it was not a randomised study, the
comparison was made with an historical control
group, and the current standard treatment for
aspergillosis was not amphotericin B deoxycho-
late, but voriconazole [43].
In conclusion, combination antifungal therapy
is more effective than monotherapy in the
management of cryptococcal meningitis and
candidaemia, but has not been assessed yet in
invasive aspergillosis. Combinations of echino-
candins with azoles or amphotericin B deserve
further well-designed studies in order to answer
the key question: is combination therapy super-
ior to monotherapy in treating invasive aspergil-
losis? In the meantime, we can only afﬁrm that
combination therapy for invasive aspergillosis is
more expensive and carries a higher risk of
toxicity and adverse drug interactions than
monotherapy.
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